🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

So lucky to have had the opportunity to work with you this year Dr. Andrew Loblaw - couldn’t have asked for a better teacher, mentor, supervisor and friend!

The prognostic importance of pattern 4 in prostate cancer outcomes- APP4 score is an easy-to-calculate, no-cost, promising marker for BF and DM. Thanks Dr. Andrew Loblaw Amar Kishan for your guidance+support!

Thrilled to share #ASCENDE-SBRT is a go with CIHR funding- will greatly impact the way we care for people with unfavourable prostate cancer. Led by the unparalleled Dr. Andrew Loblaw with an incredible team Joelle Sebastien Hotte Gerard Morton Dr. Tamim Niazi CCTG

Extended results from Alejandro (Ale) Berlin ph2 PSMA MRgRT trial for MDT of PSMA detected prostate ca oligomets + validation cohort now published IJROBP - The Red Journal - overall biochem response in 51%, med bPFS 21mo, with differences between initial vs validation cohorts. authors.elsevier.com/c/1ff8H1Hx52CH…

SBRT for oligometastasis: GUst do it? Check out our oncology scan in IJROBP - The Red Journal with oligomet experts Alejandro (Ale) Berlin @drdavidpalma Matthew P Deek C. Jillian Tsai, MD, PhD Shankar Siva Piet Ost authors.elsevier.com/a/1fvZq1Hx52CH… . Thank you Alejandro (Ale) Berlin Sue Yom IJROBP - The Red Journal for the opportunity!

🤔Can we further SMARTen up the therapeutic index of prostate #pcsm #radiotherapy? #SBRT #SABR #MRLinac Our review now in European Urology focus! authors.elsevier.com/c/1gtTb8Yy0LQm… Thank you to Alejandro (Ale) Berlin and Rachel Glicksman (Radiation Oncology Radiation Medicine Program) for the collaboration!

Excited to be back at Radiation Medicine Program Radiation Oncology after maternity leave. Thankful for the support of my department and colleagues for this special time!

RADIANT trial out now IJROBP - The Red Journal - In patients with oligoprogressive GU, breast & GI cancers treated with SBRT, >50% remain on same line systemic therapy at a year. More analyses to come Aisling Barry Joelle Radiation Medicine Program authors.elsevier.com/sd/article/S03…

Lets talk oligo-progression (limited prog met on bg of stable met dz) and our trial RADIANT! GU (46%)/Breast (33%)/GI (21%) cancers 80% 1 OP met, 1/3 liver met ☑️Feasible to accrue OP ☑️53% NO change in systemic therapy @ 1yr ☑️PFS 32% @ 1yr 1/5 redjournal.org/article/S0360-…

Thank you so much for the invitation Canadian Urological Association Tony Finelli to highlight updates in radiotherapy for localized prostate cancer and oligometastatic disease for the urology community- fantastic program & participants! Lucky to work alongside brilliant Uro-Onc colleagues.

New in the #RedJournal: Phase 2 single-arm trial of SBRT for patients with oligoprogressive breast, genitourinary and gastrointestinal cancers: by 1 yr, ~1/2 of patients could maintain their current line of systemic therapy and ~1/3 had no progression. tinyurl.com/glicksmanrj

Should regional therapy be considered the preferred treatment approach in stage 2A/B seminoma? Read about our experience and approach Princess Margaret Cancer Centre IJROBP - The Red Journal Rob Hamilton Maria Jiang redjournal.org/article/S0360-…

Congrats to Rachel Glicksman and the team Radiation Medicine Program RMP Clinical Research Program Princess Margaret Cancer Centre for publishing this Ph2 single arm study of SBRT for OPD. 🔑1yr PFS 32%; median 4.7mo overall, different by histology 🔑1 patient had Gr3 tox; overall very well tolerated 🔑No significant decline in

SBRT helps avoid SYSTEMIC THERAPY INTENSIFICATION in 50% of patients with stage IV cancer without any serious side effects in 99%. Name a single drug that can accomplish this. I’ll wait…. Jill Feldman

🎙️Can SBRT delay systemic therapy chances in oligoprogressive cancer? 🤔 OncoAlert 🩺 Objective •Assess SBRT’s ability to delay systemic therapy (ST) changes in 👥 with ≤5 progressing sites under ST 🔬 Methods •70 👥 (GU, breast, GI cancers) •Intervention: SBRT (1-5 fr) +

Radiotherapy or chemotherapy for stage 2A/B seminoma? Large institutional data suggests excellent cancer outcomes with both. Read Rachel Glicksman Rob Hamilton Maria Jiang Radiation Medicine Program et al's work in the #RedJournal. tinyurl.com/redglicks1

The Ralph Meyer Phase III Program Young Investigator Award has been awarded to Dr. Rachel Glicksman from Princess Margaret Cancer Centre recognizing her active participation and enrollment activities in #CCTG trials. #CCTG2025

Congrats Rachel Glicksman. So well deserved! The #FutureIsBright for #RadOnc Radiation Oncology